Verantos today announced it ranked 444 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year. It was the only real-world evidence-focused company on the list.
“Real-world evidence is increasingly used to augment trial results, providing insight on patient subgroups and real-world outcomes,” Verantos’ chief executive officer, Dan Riskin, said. “As such evidence has become more prominent, life sciences and evidence consumers have increased their scrutiny of evidence validity. In parallel, an artificial intelligence revolution has shined a light on the importance of data quality. As a leader in healthcare data quality, Verantos is particularly well-positioned in high-validity real-world evidence.”
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or proprietary technology that significantly contributes to the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million, with a growth rate of 50% or greater. Additionally, companies must be in business for a minimum of four years and be headquartered within North America (United States and Canada).
“This year’s rankings highlight both enduring leadership and breakthrough momentum,” said Wolfe Tone, US Deloitte Private & Emerging Client Portfolio leader and partner, Deloitte Tax LLP. “More than half of the winners are prior honorees, yet the majority of the top ten are first-time entrants — demonstrating the staying power of established leaders alongside the accelerating growth of new innovators across key sectors. As in previous years, private companies continue to dominate, underscoring the agility that private enterprises bring to competitive markets, enabling the exceptional triple and quadruple digit growth reflected in these rankings.”
About Verantos
Verantos is the global leader in high-validity real-world evidence at scale. By applying artificial intelligence to the complete patient record, Verantos enables life sciences organizations to generate high-validity evidence across therapeutic areas with measured accuracy, completeness, and traceability. Credible evidence accelerates clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives.
About the 2025 Deloitte Technology Fast 500
Now in its 31st year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2021 to 2024.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251124900412/en/
Verantos was the only real-world evidence-focused company on the Fast 500 list.
Contacts
Media contact
Dan West
marketing@verantos.com